 |
|
Multiple Myeloma Trial Results
1. Drug for Multiple Myeloma Demonstrated to Significantly Extend Disease-Free Survival
(Posted: 12/18/2009) - Initial results from a large, randomized clinical trial for patients with multiple myeloma, a cancer of the blood and bone marrow, showed that patients who received the oral drug lenalidomide (Revlimid, also known as CC-5013) following a blood stem cell transplant had their cancer kept in check longer than patients who received a placebo.
2. Thalidomide a Beneficial Option for Elderly Multiple Myeloma Patients
(Posted: 02/12/2008, Updated: 06/01/2009) - Patients aged 75 and over with newly diagnosed multiple myeloma who received the drug thalidomide in addition to standard therapy (melphalan and prednisone) survived longer than patients who received standard therapy plus a placebo, according to clinical trial results presented at the 2007 annual meeting of the American Society of Hematology.
3. Double Transplantation of One's Own Stem Cells Is Not Warranted for Multiple Myeloma
(Posted: 02/24/2009) - The addition of a second hematopoietic stem cell transplant procedure using one's own blood cells does not appear warranted in multiple myeloma, according to the Jan. 21, 2009, Journal of the National Cancer Institute.
4. Thalidomide Effective in Multiple Myeloma
(Posted: 03/15/2006, Updated: 09/16/2008) - In the March 9, 2006, issue of the New England Journal of Medicine, researchers report superior event-free and complete response rates when the drug thalidomide was used before and during primary therapy for multiple myeloma. Longer follow-up showed a survival benefit for some patients, as well.
5. Bortezomib Approved for First-Line Treatment of Multiple Myeloma
(Posted: 09/11/2008) - The targeted drug bortezomib, when added to standard therapy (melphalan and prednisone), significantly improves time to progression and overall survival in patients with newly diagnosed multiple myeloma, according to the August 28, 2008, New England journal of Medicine.
1 2 3 4 Next >
|
|
|
